![Xi Hui | Advancing Clinical Development and R&D Excellence [Portfolio Company 1-2 Monthly Report]](https://material-image.wanwang.xin/1227543910613037/WS20260521153312000001/5cedb5a7-fc18-450f-ad7d-df189af4f036.png)
Investment Activity2026/5/25
Xi·Hui | Advancing Clinical Trials, Refining R&D [Portfolio Company 1-2 Monthly Report]
Recently, the IND application for Yuguan Biological's Group B Meningococcal OMV Vaccine, a portfolio company of Kangrun Biological under Xishen Asset Management, was approved...
![Xi·Hui | Global Debut, Impressive Results [Portfolio Company 3-4 Monthly Report]](https://material-image.wanwang.xin/1227543910613037/WS20260521153312000001/652224d1-8fd3-4ba2-9a52-00116799c5aa.png)